Clinical Trial

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Name: LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) — clinical trial record (NCT06198413)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-01-08.

Status change: Recruiting → Active, Not Recruiting 2025-06-26

Trial Details

NCT Number	NCT06198413
Lead Sponsor	Innostellar Biotherapeutics Co.,Ltd
Conditions	Neovascular Age-Related Macular Degeneration
Enrollment	12 participants
Start Date	2023-02-27
Primary Completion	2024-12-26 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-01